These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28237860)

  • 1. Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
    Hattori A; Takemoto M; Tokuyama H; Koshizaka M; Yokote K
    Diabetes Res Clin Pract; 2017 Apr; 126():138-143. PubMed ID: 28237860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort.
    Deichgræber P; Witte DR; Møller HJ; Skriver MV; Richelsen B; Jørgensen ME; Johansen NB; Sandbæk A
    Diabetologia; 2016 Nov; 59(11):2467-2476. PubMed ID: 27541014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
    Kato H; Nagai Y; Ohta A; Tenjin A; Nakamura Y; Tsukiyama H; Sasaki Y; Fukuda H; Ohshige T; Terashima Y; Sada Y; Kondo A; Sasaoka T; Tanaka Y
    Diabetes Res Clin Pract; 2015 Jul; 109(1):199-205. PubMed ID: 25934525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
    Oe H; Nakamura K; Kihara H; Shimada K; Fukuda S; Takagi T; Miyoshi T; Hirata K; Yoshikawa J; Ito H;
    Cardiovasc Diabetol; 2015 Jun; 14():83. PubMed ID: 26084668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity.
    Sporrer D; Weber M; Wanninger J; Weigert J; Neumeier M; Stögbauer F; Lieberer E; Bala M; Kopp A; Schäffler A; Buechler C
    Eur J Clin Invest; 2009 Aug; 39(8):671-9. PubMed ID: 19490068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function.
    Semnani-Azad Z; Connelly PW; Johnston LW; Retnakaran R; Harris SB; Zinman B; Hanley AJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e285-94. PubMed ID: 31677389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
    Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.
    Aso Y; Fukushima M; Sagara M; Jojima T; Iijima T; Suzuki K; Momobayashi A; Kasai K; Inukai T
    Diabetes Res Clin Pract; 2015 Dec; 110(3):250-6. PubMed ID: 26508675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An alternatively activated macrophage marker CD163 in severely obese patients: the influence of very low-calorie diet and bariatric surgery.
    Cinkajzlová A; Lacinová Z; Kloučková J; Kaválková P; Trachta P; Kosák M; Krátký J; Kasalický M; DoleŽalová K; Mráz M; Haluzík M
    Physiol Res; 2017 Sep; 66(4):641-652. PubMed ID: 28406702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus.
    Grannes H; Ueland T; Simeone P; Liani R; Guagnano MT; Aukrust P; Michelsen AE; Birkeland K; di Castelnuovo A; Cipollone F; Consoli A; Halvorsen B; Gregersen I; Santilli F
    Cardiovasc Diabetol; 2024 Apr; 23(1):146. PubMed ID: 38685051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss.
    Fjeldborg K; Christiansen T; Bennetzen M; J Møller H; Pedersen SB; Richelsen B
    Obesity (Silver Spring); 2013 Dec; 21(12):2437-43. PubMed ID: 23512476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
    Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Inoue A; Atsumi T; Manda N; Kurihara Y; Aoki S;
    PLoS One; 2016; 11(10):e0164255. PubMed ID: 27711199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
    Sakura H; Hashimoto N; Sasamoto K; Ohashi H; Hasumi S; Ujihara N; Kasahara T; Tomonaga O; Nunome H; Honda M; Iwamoto Y;
    BMC Endocr Disord; 2016 Dec; 16(1):70. PubMed ID: 27905912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
    J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum soluble CD163 predicts risk of type 2 diabetes in the general population.
    Møller HJ; Frikke-Schmidt R; Moestrup SK; Nordestgaard BG; Tybjærg-Hansen A
    Clin Chem; 2011 Feb; 57(2):291-7. PubMed ID: 21106861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD163: a biomarker linking macrophages and insulin resistance.
    Parkner T; Sørensen LP; Nielsen AR; Fischer CP; Bibby BM; Nielsen S; Pedersen BK; Møller HJ
    Diabetologia; 2012 Jun; 55(6):1856-62. PubMed ID: 22450890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.